8月1日，科美诊断今日收盘8.49元，上涨6.66%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到32.99倍，创113天以来新低，总市值34.05亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均53.65倍，行业中值37.22倍，科美诊断排 名第68位。 股东方面，截至2025年3月31日，科美诊断股东户数11024户，较上次增加1412户，户均持股市值35.28 万元，户均持股数量2.76万股。 科美诊断技术股份有限公司的主营业务是临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售。 公司的主要产品是LiCA系列产品、CC系列产品。报告期内，公司新获得境内外授权专利64项，其中境 内发明专利33项，境内实用新型专利20项，外观设计专利11项。展现出公司持续壮大的创新能力和技术 储备。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断32.9926.802.3834.05亿行业平均 53.655 ...

金融界消息 截至2025年8月1日收盘，科美诊断（688468）报收于8.49元，上涨6.66%，换手率6.54%， 成交量26.23万手，成交金额2.20亿元。 天眼查商业履历信息显示，科美诊断技术股份有限公司，成立于2007年，位于北京市，是一家以从事专 业技术服务业为主的企业。企业注册资本40110.8万人民币，实缴资本36000万人民币。公司法定代表人 为李临。 科美诊断最新一期业绩显示，截至2025一季报，公司营业总收入8130.01万元、同比减少27.01%，归属 净利润1454.28万元，同比减少62.12%，扣非净利润1113.14万元，同比减少68.00%，流动比率7.125、速 动比率6.374、资产负债率21.19%。 来源：金融界 资金流向方面，今日主力资金净流入2669.99万元，占比成交额12.15%。其中，超大单净流入35.50万 元、占成交额0.16%，大单净流入2634.49万元、占成交额11.99%，中单净流出流出811.85万元、占成交 额3.69%，小单净流出1858.14万元、占成交额8.46%。 通过天眼查大数据分析，科美诊断技术股份有限公司共对外投资了3家企业，参 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a significant decline in revenue and net profit in the latest quarterly report [1][2] - Kemei Diagnostics' stock closed at 7.99 yuan, with a rolling PE ratio of 31.05, marking a new low in 90 days, and a total market capitalization of 3.205 billion yuan [1] - The company ranks 63rd in the medical device industry, which has an average PE ratio of 55.28 and a median of 38.06 [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company has obtained 64 new domestic and international patents during the reporting period, showcasing its growing innovation capability and technological reserves [1] Group 3 - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics, which has a current PE ratio of 30.46, significantly lower than the industry average of 54.56 [1][2] - Kemei Diagnostics has a total market capitalization of 3.145 billion yuan, ranking 62nd in the medical device industry based on PE ratio [1][2] - The company has seen an increase in shareholder numbers, with 11,024 shareholders as of March 31, 2025, an increase of 1,412 from the previous count [1] Group 2 - Kemei Diagnostics specializes in the research, development, production, and sales of clinical immunochemistry diagnostic reagents and instruments, with key products including the LiCA and CC series [1] - The company has demonstrated strong innovation capabilities, acquiring 64 new domestic and international patents during the reporting period, including 33 domestic invention patents [1] - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported a revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12% [1]

7月18日，科美诊断今日收盘7.73元，上涨2.11%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到30.04倍，创77天以来新低，总市值31.01亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均52.34倍，行业中值36.99倍，科美诊断排 名第64位。 股东方面，截至2025年3月31日，科美诊断股东户数11024户，较上次增加1412户，户均持股市值35.28 万元，户均持股数量2.76万股。 科美诊断技术股份有限公司的主营业务是临床免疫化学发光诊断检测试剂和仪器的研发、生产和销售。 公司的主要产品是LiCA系列产品、CC系列产品。报告期内，公司新获得境内外授权专利64项，其中境 内发明专利33项，境内实用新型专利20项，外观设计专利11项。展现出公司持续壮大的创新能力和技术 储备。 最新一期业绩显示，2025年一季报，公司实现营业收入8130.01万元，同比-27.01%；净利润1454.28万 元，同比-62.12%，销售毛利率66.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13科美诊断30.0424.402.1731.01亿行业平均 52.344 ...

Group 1 - The State Intellectual Property Office of China shows that Komei Diagnostic Technology Co., Ltd. and Komei Boyang Diagnostic Technology (Shanghai) Co., Ltd. have applied for a patent titled "Preparation Method and Application of Biotin-Labeled Small Molecules," with publication number CN120214293A and application date of December 2023 [1] - The patent involves a method for preparing biotin-labeled small molecules, which includes mixing small molecules with an activator to obtain activated small molecule reagents, where the molecular weight of the small molecules is less than 1000 Da, and then reacting the activated small molecule reagents with biotin-labeled marker reagents, where the molecular weight of the biotin-labeled markers is between 1000 Da and 10000 Da [1] - Komei Diagnostic Technology Co., Ltd. was established in 2007 in Beijing, focusing on professional technical services, with a registered capital of 401.108 million RMB, and has invested in 3 companies, participated in 74 bidding projects, and holds 475 patents [1] Group 2 - Komei Boyang Diagnostic Technology (Shanghai) Co., Ltd. was established in 2005 in Shanghai, primarily engaged in pharmaceutical manufacturing, with a registered capital of 34.088364 million RMB, and has invested in 1 company, participated in 87 bidding projects, and holds 315 patents [2] - The company has 36 trademark registrations and 126 administrative licenses [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics in the medical device industry, indicating a lower PE ratio compared to industry averages [1][2] - Kemei Diagnostics closed at 7.11 yuan, with a PE ratio of 27.63, while the industry average PE is 48.89 [1][2] - The company's total market capitalization is 2.852 billion yuan, ranking 64th in the industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, nine institutions hold shares in Kemei Diagnostics, with a total holding of 206.2876 million shares valued at 1.537 billion yuan [1] - The main business of Kemei Diagnostics includes the research, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company has obtained 64 new domestic and international patents during the reporting period, showcasing its innovation capabilities [1] Group 3 - In the latest performance report for the first quarter of 2025, Kemei Diagnostics reported revenue of 81.3001 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.5428 million yuan, down 62.12% [1] - The gross profit margin for the company stands at 66.88% [1]

Group 1 - The core viewpoint of the news is that Kemei Boyang Diagnostic Technology (Shanghai) Co., Ltd. has applied for a patent for a multi-needle sampling arm structure and a fully automated chemiluminescence immunoassay analyzer, indicating innovation in diagnostic technology [1] - The patent application was filed on December 2023, with the publication number CN120142687A, showcasing the company's commitment to advancing medical diagnostic equipment [1] - The patent describes a compact structure that includes a sampling arm body, a reagent needle group, and a driving mechanism group, which allows for vertical arrangement and independent movement of the sampling needles, enhancing efficiency and reducing space occupation [1] Group 2 - Kemei Boyang Diagnostic Technology (Shanghai) Co., Ltd. was established in 2005, located in Shanghai, with a registered capital of 34.088364 million RMB, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has made investments in one other enterprise, participated in 87 bidding projects, and holds 36 trademark records and 309 patent records, along with 126 administrative licenses [2] - Kemei Diagnostic Technology Co., Ltd. was founded in 2007 in Beijing, with a registered capital of 40.1108 million RMB, focusing on professional technical services [2] - This company has invested in three other enterprises, participated in 74 bidding projects, and possesses 360 trademark records and 467 patent records, along with 110 administrative licenses [2]

Core Viewpoint - The company has announced a cash dividend distribution plan for the fiscal year 2024, with a proposed cash dividend of CNY 0.1250 per share, approved at the annual shareholders' meeting on May 19, 2025 [2][4]. Summary by Sections Dividend Distribution Plan - The cash dividend distribution is based on a total share capital of 401,108,000 shares, with 6,514,913 shares in the company's repurchase account excluded, resulting in a base of 394,593,087 shares for the distribution [4]. - The total cash dividend to be distributed amounts to CNY 49,324,135.88, which represents 38.82% of the company's net profit attributable to shareholders for the fiscal year 2024 [4]. Shareholder Eligibility - All shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the day before the dividend distribution date are eligible for the cash dividend [3]. Taxation Details - For individual shareholders holding unrestricted shares, dividends are subject to different tax treatments based on the holding period. Those holding shares for over one year are exempt from individual income tax, while those holding for one year or less will have taxes withheld upon transfer [9][10]. - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of CNY 0.1125 per share after tax [11]. Implementation Method - The company will distribute cash dividends through the China Securities Depository and Clearing Corporation Limited, with specific arrangements for shareholders who have completed designated transactions [7][8].

88 Vin Chana Poad Midd 上海市通力律师事务所 关于科美诊断技术股份有限公司 差异化分红事项之专项法律意见书 致:科美诊断技术股份有限公司 上海市通力律师事务所(以下简称"本所")接受科美诊断技术股份有限公司(以下简称 "科美诊断"或"公司")的委托,指派本所朱晓明律师、黄雅程律师(以下合称"本所律师") 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以 下简称"《证券法》")、《上海证券交易所上市公司自律监管指引第 7 号 -- 回购股份》(以 下简称"《自律监管指引》")、《上海证券交易所上市公司自律监管指南第２号——业务 办理》等法律、法规及规范性文件(以下简称"法律、法规及规范性文件",该等法律、法 规及规范性文件不包括香港特别行政区、澳门特别行政区和台湾地区的法律法规)以及《科 美诊断技术股份有限公司章程》(以下简称"《公司章程》")的规定,就科美诊断 2024 年 度利润分配所涉及的差异化分红事项(以下简称"本次差异化分红")相关事项出具法律意见。 为出具本法律意见书,本所律师已经严格履行法定职责,遵循了勤勉尽责和诚实信用 原则,对科美诊断本 ...